677:"EVP-6124, an alpha-7 nicotinic partial agonist, produces positive effects on cognition, clinical function, and negative symptoms in patients with chronic schizophrenia on stable antipsychotic therapy: abstract accepted for presentation at the 50th Annual Meeting of the American College of Neuropsychopharmacology"
180:
after the patient and informant interviews have been completed. For the patient and informant interviews, the global rating reflects the overall impression of the patient’s level of cognitive difficulty across the 20 areas of cognition assessed and is rated on a scale of 1–10. Higher ratings indicate
117:
The SCoRS is a 20 item interview-based clinical assessment containing questions about the patient’s ability to manage cognitively demanding, functionally relevant, everyday tasks such as conversations, watching television, and using electronic devices. The items were developed to assess the following
595:
Green, M.; Nuechterlein, K.; Kern, R.; Baade, L.; Fenton, W.; Gold, J.M.; Keefe, R.S.; Mesholam-Gately, R.; Seidman, L.J.; Stover, E.; Marder, S.R. (February 2008). "Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and
Standardization Study".
96:
In addition to the 20 individual items, there is also a global rating assigned by the clinician after both interviews have been completed that draws upon information gained from the patient, informant, and the interviewer’s clinical judgment. Each interview averages 10–15 minutes in length with the
176:?”. Each item is rated on a 4-point scale ranging from “No Impairment” to “Severe Impairment”. A rating of “Not Applicable” is also possible if a particular question does not apply to an individual patient. In addition to the 20 individual items, there is also a global rating assigned by the
298:
In addition, the cognitive domains assessed by the SCoRS also correspond with the seven cognitive domains identified by experts from an initiative established by the NIMH MATRICS project which strengthens the SCoRS’ attractiveness as a co-primary measure for
448:
Keefe, R.S.; Poe, M.; Walker, T.M.; Kang, J.W.; Harvey, P.D. (March 2006). "The
Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity".
312:
631:
Harvey, P.D.; Ogasa, M.; Cucchiaro, J.; Loebel, A.; Keefe, R.S. (April 2011). "Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone".
171:
and they are reliably associated with functional outcomes. Two examples of items from the SCoRS are, “Do you have difficulty with remembering names of people you know?” and “Do you have difficulty following a
303:
cognition trials. Data from recent research also suggest that the SCoRS has potential as a clinically relevant measure in a clinical practice setting due to its sensitivity to treatment effects.
492:
Keefe, Richard S.E.; Davis, Vicki G.; Spagnola, Nathan B.; Hilt, Dana; Dgetluck, Nancy; Ruse, Stacy; Patterson, Thomas L.; Narasimhan, Meera; Harvey, Philip D. (February 2015).
549:
Buchanan, R.W.; Davis, M.; Goff, D.; Green, M.F.; Keefe, R.S.; Leon, A.C.; Nuechterlein, K.H.; Laughren, T.; Levin, R.; Stover, E.; Fenton, W.; Marder, S.R. (February 2005).
700:"Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia"
109:
free from distractions. The informant interview can also be administered over the phone if the informant is unable to be physically present at the clinician’s office.
210:
105:, averages 20–30 minutes. The SCoRS requires no additional equipment beyond the paper administration form and is ideally administered in a quiet
345:
Keefe, R.S.; Davis, V.G.; Spagnola, N.B.; Hilt, D.; Dgetluck, N.; Ruse, S.; Patterson, T.L.; Narasimhan, M.; Harvey, P.D. (February 2015).
206:
81:
for the patient (ideally a person who has regular contact with the patient in everyday situations, such as a family member, friend, or
205:
for pivotal registration trials. As an interview-based assessment of cognition, the SCoRS meets the criteria established by the FDA
676:
40:
698:
Keefe, R.S.; Meltzer, H.A.; Dgetluck, N.; Gawryl, M.; Koenig, G.; Moebius, H.J.; Lombardo, I.; Hilt, D.C. (December 2015).
202:
551:"A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia"
827:
287:
106:
78:
214:
101:
preferably completed prior to the informant interview. Total assessment time for the SCoRS, including
98:
141:
657:
474:
32:
48:
778:
729:
649:
613:
572:
531:
513:
466:
427:
376:
675:
Hilt, D.; Meltzer, H.; Gawry, M.; Ward, S.; Dgetluck, N.; Bhuvaneswaran, C. (February 2008).
494:"Reliability, Validity and Treatment Sensitivity of the Schizophrenia Cognition Rating Scale"
347:"Reliability, Validity and Treatment Sensitivity of the Schizophrenia Cognition Rating Scale"
768:
760:
719:
711:
641:
605:
562:
521:
505:
458:
417:
407:
366:
358:
161:
173:
151:
102:
773:
748:
724:
699:
526:
493:
422:
395:
371:
346:
136:
52:
749:"The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia"
684:
821:
764:
300:
232:
198:
194:
190:
168:
509:
478:
362:
189:
The SCoRS is currently being used as a co-primary endpoint in several international
661:
609:
281:
Harvey et al, 2011; Hilt et al, 2011; Keefe, Davis, et al, 2014; Keefe et al, 2015
167:
These areas were chosen because they are often severely impaired in patients with
67:
The SCoRS assessment collects information generated from three different sources:
645:
44:
243:
156:
82:
462:
36:
517:
396:"The clinical utility of lurasidone in schizophrenia: patient considerations"
39:
patients’ day-to-day functioning. It was originally developed in 2001 at the
567:
550:
177:
146:
126:
119:
89:
28:
782:
733:
653:
617:
576:
535:
470:
431:
380:
715:
56:
211:
Measurement and
Treatment Research to Improve Cognition in Schizophrenia
412:
313:
University of
California, San Diego Performance-Based Skills Assessment
72:
799:
131:
812:
92:
who administered the scale to the patient and informant.
802:-Virtual Reality Functional Capacity Assessment Tool
213:(MATRICS) panel for co-primary outcome measures for
254:
Meaningful correlations with real-world functioning
88:A rating based on the clinical judgment of the
340:
338:
336:
334:
332:
330:
328:
8:
590:
588:
586:
443:
441:
237:Keefe, Davis, et al, 2014 Green et al, 2008
681:American College of Neuropsychopharmacology
31:-based clinical assessment that evaluates
772:
723:
566:
525:
421:
411:
370:
219:
197:assessing cognitive treatment change in
324:
35:and the degree to which these deficits
400:Neuropsychiatric Disease and Treatment
16:Schizophrenia clinical assessment tool
7:
21:Schizophrenia Cognition Rating Scale
207:National Institute of Mental Health
753:Dialogues in Clinical Neuroscience
451:The American Journal of Psychiatry
14:
794:Other Cognitive Assessment Tools
498:European Neuropsychopharmacology
510:10.1016/j.euroneuro.2014.06.009
363:10.1016/j.euroneuro.2014.06.009
181:greater degrees of impairment.
765:10.31887/DCNS.2006.8.1/smarder
610:10.1176/appi.ajp.2007.07010089
598:American Journal of Psychiatry
201:and has been permitted by the
41:Duke University Medical Center
1:
646:10.1016/j.schres.2011.01.004
215:cognitive enhancement trials
59:, and in clinical settings.
747:Marder, S.R. (March 2006).
262:Practical for experimenters
185:Use and Supporting Research
844:
463:10.1176/appi.ajp.163.3.426
257:Keefe, Davis, et al, 2014
249:Keefe, Davis, et al, 2014
246:with cognitive performance
394:Harvey, P. (April 2015).
351:Eur. Neuropsychopharmacol
47:and is licensed through
704:Neuropsychopharmacology
233:Test-Retest Reliability
51:. The SCoRS is used in
683:. ACNP. Archived from
634:Schizophrenia Research
555:Schizophrenia Bulletin
288:interrater reliability
270:Tolerable for patients
71:An interview with the
568:10.1093/schbul/sbi020
278:Treatment Sensitivity
77:An interview with an
716:10.1038/npp.2015.176
226:Supporting Research
292:Keefe et al, 2006;
142:Language Production
413:10.2147/NDT.S68417
273:Green et al, 2008
265:Green et al, 2008
217:in schizophrenia.
33:cognitive deficits
710:(13): 3053–3060.
296:
295:
57:academic research
45:Dr. Richard Keefe
835:
813:Official website
787:
786:
776:
744:
738:
737:
727:
695:
689:
688:
672:
666:
665:
640:(1–3): 188–194.
628:
622:
621:
592:
581:
580:
570:
546:
540:
539:
529:
489:
483:
482:
445:
436:
435:
425:
415:
391:
385:
384:
374:
342:
220:
162:Social Cognition
843:
842:
838:
837:
836:
834:
833:
832:
828:Cognitive tests
818:
817:
809:
796:
791:
790:
746:
745:
741:
697:
696:
692:
674:
673:
669:
630:
629:
625:
594:
593:
584:
548:
547:
543:
491:
490:
486:
447:
446:
439:
393:
392:
388:
344:
343:
326:
321:
309:
187:
152:Problem Solving
115:
65:
53:clinical trials
27:) is a 20 item
17:
12:
11:
5:
841:
839:
831:
830:
820:
819:
816:
815:
808:
807:External links
805:
804:
803:
795:
792:
789:
788:
759:(1): 109–113.
739:
690:
687:on 2016-05-21.
667:
623:
604:(2): 221–228.
582:
541:
504:(2): 176–184.
484:
457:(3): 426–432.
437:
386:
357:(2): 176–184.
323:
322:
320:
317:
316:
315:
308:
305:
294:
293:
290:
283:
282:
279:
275:
274:
271:
267:
266:
263:
259:
258:
255:
251:
250:
247:
239:
238:
235:
228:
227:
224:
195:phase 3 trials
186:
183:
165:
164:
159:
154:
149:
144:
139:
137:Working Memory
134:
129:
114:
113:Administration
111:
94:
93:
86:
75:
64:
61:
15:
13:
10:
9:
6:
4:
3:
2:
840:
829:
826:
825:
823:
814:
811:
810:
806:
801:
798:
797:
793:
784:
780:
775:
770:
766:
762:
758:
754:
750:
743:
740:
735:
731:
726:
721:
717:
713:
709:
705:
701:
694:
691:
686:
682:
678:
671:
668:
663:
659:
655:
651:
647:
643:
639:
635:
627:
624:
619:
615:
611:
607:
603:
599:
591:
589:
587:
583:
578:
574:
569:
564:
560:
556:
552:
545:
542:
537:
533:
528:
523:
519:
515:
511:
507:
503:
499:
495:
488:
485:
480:
476:
472:
468:
464:
460:
456:
452:
444:
442:
438:
433:
429:
424:
419:
414:
409:
406:: 1103–1109.
405:
401:
397:
390:
387:
382:
378:
373:
368:
364:
360:
356:
352:
348:
341:
339:
337:
335:
333:
331:
329:
325:
318:
314:
311:
310:
306:
304:
302:
301:schizophrenia
291:
289:
285:
284:
280:
277:
276:
272:
269:
268:
264:
261:
260:
256:
253:
252:
248:
245:
241:
240:
236:
234:
230:
229:
225:
222:
221:
218:
216:
212:
208:
204:
200:
199:schizophrenia
196:
192:
184:
182:
179:
175:
170:
169:schizophrenia
163:
160:
158:
155:
153:
150:
148:
145:
143:
140:
138:
135:
133:
130:
128:
125:
124:
123:
121:
112:
110:
108:
104:
100:
91:
87:
84:
83:social worker
80:
76:
74:
70:
69:
68:
62:
60:
58:
54:
50:
46:
42:
38:
34:
30:
26:
22:
756:
752:
742:
707:
703:
693:
685:the original
680:
670:
637:
633:
626:
601:
597:
558:
554:
544:
501:
497:
487:
454:
450:
403:
399:
389:
354:
350:
297:
244:correlations
188:
166:
157:Motor Skills
116:
95:
66:
49:WCG Clinical
24:
20:
18:
561:(1): 5–19.
242:Meaningful
107:environment
63:Description
319:References
122:domains:
518:0924-977X
178:clinician
147:Reasoning
127:Attention
120:cognitive
99:interview
90:clinician
79:informant
29:interview
822:Category
783:16640121
734:26089183
654:21277745
618:18172017
577:15888422
536:25028065
479:27495774
471:16513863
432:25995636
381:25028065
307:See also
223:Criteria
97:patient
774:3181758
725:4864641
662:8805912
527:4277931
423:4425313
372:4277931
286:Strong
231:Strong
209:(NIMH)
191:phase 2
174:TV show
103:scoring
73:patient
800:VRFCAT
781:
771:
732:
722:
660:
652:
616:
575:
534:
524:
516:
477:
469:
430:
420:
379:
369:
132:Memory
37:impair
658:S2CID
475:S2CID
25:SCoRS
779:PMID
730:PMID
650:PMID
614:PMID
573:PMID
532:PMID
514:ISSN
467:PMID
428:PMID
377:PMID
193:and
19:The
769:PMC
761:doi
720:PMC
712:doi
642:doi
638:127
606:doi
602:165
563:doi
522:PMC
506:doi
459:doi
455:163
418:PMC
408:doi
367:PMC
359:doi
203:FDA
43:by
824::
777:.
767:.
755:.
751:.
728:.
718:.
708:40
706:.
702:.
679:.
656:.
648:.
636:.
612:.
600:.
585:^
571:.
559:31
557:.
553:.
530:.
520:.
512:.
502:25
500:.
496:.
473:.
465:.
453:.
440:^
426:.
416:.
404:11
402:.
398:.
375:.
365:.
355:25
353:.
349:.
327:^
55:,
785:.
763::
757:8
736:.
714::
664:.
644::
620:.
608::
579:.
565::
538:.
508::
481:.
461::
434:.
410::
383:.
361::
85:)
23:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.